Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06506565 · ClinicalTrials.gov registry record · Phase 4
Low-Dose Ketamine Infusion During Burn Wound Care
A Phase 4 study of Pain and Burn, sponsored by University of Tennessee.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06506565: Recruiting Phase 4 study of Pain and Burn, sponsored by University of Tennessee.
NCT06506565 is a Phase 4 study of Pain and Burn that is actively recruiting participants, run by University of Tennessee. The registered enrollment target is 140 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06506565, a Phase 4 study of Pain and Burn, is actively recruiting participants, sponsored by University of Tennessee.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.
Primary Outcome
Numeric Pain Rating Scale (0 - 10, with 0 being absence of pain and 10 being the worst pain imaginable)
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG 0.9% NaCl
Study Locations (1)
Tennessee
- Regional One Health - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-07-08 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What NCT06506565 shows while recruiting
NCT06506565 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (54% lower).
The record links to 4 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT06506565 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06506565 about?
NCT06506565 is a clinical study titled "Low-Dose Ketamine Infusion During Burn Wound Care". The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine...
What is the current status of trial NCT06506565?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2024-07-08. Estimated completion is 2025-12.
What conditions does trial NCT06506565 study?
This clinical trial studies the following conditions: Pain, Burn, Dissociation, Opioid.
What interventions are being tested in trial NCT06506565?
The interventions under investigation include: Ketamine (DRUG), 0.9% NaCl (DRUG).
Who is sponsoring clinical trial NCT06506565?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06506565 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06506565's enrollment target sits among peer trials
140 123rd of 374 higher than 252 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Magnesium on Neuromonitoring
RECRUITING · Phase 4
-
Optimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery
RECRUITING · Phase 4
-
Optimizing Pain Control in Transurethral Resection of the Prostate
RECRUITING · Phase 4
-
Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
RECRUITING · Phase 4
-
Regional Blocks for Lateral Condyle Fractures
RECRUITING · Phase 4
-
Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty)
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI